Moncef Slaoui resigns from post-GlaxoSmithKline home Medicxi after harassment allegations
Moncef Slaoui has stepped down from the European VC firm Medicxi, effectively completing his exodus from executive and board positions after GlaxoSmithKline substantiated sexual harassment allegations against him earlier this week.
Medicxi had been Slaoui’s main professional home in the three years before he took the scientific lead in the Trump Administration’s Operation Warp Speed, helping companies accelerate and scale the first wave of Covid-19 vaccines. He took a position there as a partner three months after retiring as GSK’s R&D chief in 2017, most recently helping them launch Centessa, a well-heeled biotech based off a similar model he set up within GSK. Slaoui stepped down from Centessa on Thursday.
Medicxi announced Slaoui’s departure in a three-sentence statement Friday. “We would like to re-state that Medicxi’s values are based on respect, trust and teamwork, and we are committed to working in an environment which reflects such values and culture,” they wrote.
Slaoui had already signaled he would leave Medicxi, writing in a public apology Wednesday that he was “taking a leave of absence from my current professional responsibilities effective immediately, to focus on my family.”
GSK announced Wednesday morning that they fired Slaoui from his position as chairman of the board of Galvani Bioelectronics, a company majority owned by GSK. The British drugmaker received a complaint in February, CEO Emma Walmsley wrote in a memo to employees, and hired an outside firm to launch an investigation, which ultimately substantiated the allegations.
Slaoui, having led Warp Speed since last May, announced his resignation in January, eight days before President Biden’s inauguration.